Company intelligence / Profile preview

Beisike

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Besike is a clinical-stage Chinese biotechnology company focused on the development of innovative therapies for autoimmune and inflammatory diseases. The company specializes in the research and development of recombinant proteins and monoclonal antibodies targeting key inflammatory pathways such as IL-17 and TNF-alpha. Besike's lead programs are aimed at treating chronic conditions including plaque psoriasis and ankylosing spondylitis. By leveraging its internal R&D capabilities, the company aims to provide high-quality, affordable biological treatments for patients in the Chinese market and beyond.

Therapeutic areas: ImmunologyRheumatologyDermatology
Modalities: Recombinant proteinMonoclonal antibodySmall molecule
Industry: Biotech

Beyond the preview

Go deeper on Beisike.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beisike.

Explore the full profile